SPRO Spero Therapeutics |
$2.12 -3.0% |
-25.8%
 |
IBI355
Third-Generation Anti-CD40L Antibody
|
|
7/14/2026 - Provided Update
Innovent Biologics, Inc. and Spero Therapeutics, Inc. announced an exclusive license agreement for I… Full Summary
|
SPRO Spero Therapeutics |
$2.12 -3.0% |
-25.8%
 |
IBI355
Third-Generation Anti-CD40L Antibody
|
Phase 2
|
7/14/2026 - Provided Update
Innovent Biologics, Inc. and Spero Therapeutics, Inc. currently expects to advance IBI355 into a Pha… Full Summary
|
RNA Avidity Biosciences |
$12.13 -0.7% |
-1.9%
 |
ATR 1072
Treatment of PRKAG2 Syndrome
|
|
7/14/2026 - FDA approved
Atrium Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its… Full Summary
|
KURA Kura Oncology |
$11.14 +2.1% |
+23.0%
 |
FIT-001
patients with KRAS G12C-mutated advanced solid tumors.
|
Phase 1a
|
7/14/2026 - Results
Kura Oncology, Inc. announced that updated Phase 1a results from the ongoing FIT-001 Phase 1a/1b cl… Full Summary
|
AVIR Atea Pharmaceuticals |
$4.80 +1.2% |
+6.8%
 |
AT-587
Treatment of Hepatitis E Virus
|
Phase 1
|
7/14/2026 - Initiation
Atea Pharmaceuticals, Inc announced the initiation of a first-in-human Phase 1 clinical trial evalu… Full Summary
|
IRWD Ironwood Pharmaceuticals |
$4.08 -3.1% |
+11.7%
 |
apraglutide
For patients with short bowel syndrome (SBS) with intestinal failure (IF)
|
Phase 3
|
7/14/2026 - Provided Update
Ironwood Pharmaceuticals, Inc announced that the confirmatory Phase 3 STARS-2 trial of apraglutide … Full Summary
|
COAG Hemab Therapeutics |
$39.72 +0.5% |
+59.0%
 |
HMB-002
in Von Willebrand disease
|
|
7/14/2026 - Data Presentation
Hemab Therapeutics today presented clinical and preclinical data from sutacimig in GT and FVIID at t… Full Summary
|
A Agilent Technologies |
$133.91 -0.1% |
+3.2%
 |
PD‑L1 IHC 28‑8
treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG®
|
|
7/14/2026 - FDA approved
Agilent Technologies Inc. announced that it has received U.S. Food and Drug Administration (FDA) a… Full Summary
|
SUPN Supernus Pharmaceuticals |
$47.00 -0.7% |
+5.8%
 |
Qelbree (SPN-812)
ADHD in pediatric patients
|
|
7/14/2026 - Provided Update
Supernus Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing pro… Full Summary
|
BIIB Biogen |
$192.86 -7.7% |
-3.6%
 |
diranersen
Alzheimer’s disease
|
Phase 2
|
7/14/2026 - Data
Biogen Inc. announced data from the Phase 2 CELIA study evaluating diranersen, an investigational an… Full Summary
|
INCY Incyte |
$113.59 -0.6% |
+4.7%
 |
VGA039
Patients with all Von Willebrand Disease Types
|
|
7/13/2026 - Efficacy and Safety Data
Incyte announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1… Full Summary
|
ANIP ANI Pharmaceuticals |
$81.31 +0.3% |
-0.5%
 |
SYNCHRONICITY
in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).
|
Phase 4
|
7/13/2026 - Top-line data
ANI Pharmaceuticals, Inc nnounced positive topline data from its Phase 4, open-label, single-arm SYN… Full Summary
|
QTTB Q32 Bio |
$21.90 +2.4% |
+73.3%
 |
Bempikibart
For Severe Alopecia Areata
|
|
7/13/2026 - Top-line results
Q32 Bio Inc announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinica… Full Summary
|
IONS Ionis Pharmaceuticals |
$55.70 -1.9% |
-24.0%
 |
ION337
Dravet syndrome
|
|
7/13/2026 - Dose Update
Ionis Pharmaceuticals, Inc announced that the first participant has been dosed in the Phase 1-2 ASCE… Full Summary
|
BMY Bristol Myers Squibb |
$57.86 -2.5% |
+1.4%
 |
MeziKd
Relapsed or Refractory Multiple Myeloma
|
NDA
|
7/13/2026 - FDA Accepted
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted a New … Full Summary
|
BMY Bristol Myers Squibb |
$57.86 -2.5% |
+1.4%
 |
MeziKd
Relapsed or Refractory Multiple Myeloma
|
NDA Target date: May 13, 2027
|
7/13/2026 - PDUFA Date
Bristol Myers Squibb announced that The U.S. FDA has assigned a target action date of May 13, 2027 Full Summary
|
OCGN Ocugen |
$1.42 +0.4% |
+16.9%
 |
OCU400 (AAV5-hNR2E3)
Retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA).
|
|
7/13/2026 - Provided Update
Ocugen, Inc announced the signing of a binding term sheet to negotiate and enter into a license agre… Full Summary
|
IONS Ionis Pharmaceuticals |
$55.70 -1.9% |
-24.0%
 |
ION337
Dravet syndrome
|
Phase 1
|
7/13/2026 - Dose Update
Ionis Pharmaceuticals, Inc announced that the first participant has been dosed in the Phase 1-2 AS… Full Summary
|
ALGS Aligos Therapeutics |
$6.40 +0.6% |
+21.2%
 |
pevifoscorvir sodium
chronic hepatitis B virus infection
|
|
7/13/2026 - Enrollment Update
Aligos Therapeutics, Inc. announced that it has completed enrollment of both the HBeAg+ (Part 1a) a… Full Summary
|
ENLV Enlivex Therapeutics |
$6.29 -5.8% |
-37.5%
 |
Allocetra
Sepsis
|
RMAT Designation
|
7/13/2026 - Designation Grant
Enlivex Ltd announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medi… Full Summary
|
IMMP Prima BioMed |
$0.44 -2.1% |
+21.3%
 |
eftilagimod alpha
For cancer and autoimmune disease
|
|
7/13/2026 - Provided Update
Immutep Limited announced a significant positive update of the investigator-initiated INSIGHT-003 Ph… Full Summary
|
VYGR Voyager Therapeutics |
$3.22 -0.6% |
-8.0%
 |
VY1706
for Alzheimer's disease
|
|
7/13/2026 - Data Presentation
Voyager Therapeutics, today presented six-month good laboratory practice (GLP) toxicology data for … Full Summary
|
NAGE Niagen Bioscience |
$3.37 -3.0% |
-2.5%
 |
NB4168
Treatment Of Ataxia Telangiectasia
|
RPD Designation
|
7/13/2026 - Designation Grant
NNiagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For… Full Summary
|
BMRN BioMarin Pharmaceutical |
$58.55 -1.1% |
+4.6%
 |
vosoritide
Children with achondroplasia
|
supplemental New Drug Application (sNDA)
|
7/13/2026 - FDA Accepted
BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accept… Full Summary
|
BMRN BioMarin Pharmaceutical |
$58.55 -1.1% |
+4.6%
 |
vosoritide
Children with achondroplasia
|
supplemental New Drug Application (sNDA) Target date: February 28, 2027
|
7/13/2026 - PDUFA Date
BioMarin Pharmaceutical Inc. announced that The FDA has set a Prescription Drug User Fee Act (PDUFA… Full Summary
|
ONCY Oncolytics Biotech |
$0.94 +1.6% |
+17.6%
 |
Pelareorep
In Breast Cancer
|
|
7/13/2026 - Provided Update
Oncolytics Biotech® Inc. today provided a clinical and regulatory update on REO 033, the Company’s r… Full Summary
|
MESO Mesoblast |
$16.74 +3.2% |
+20.2%
 |
rexlemestrocel-L
For Chronic Low Back Pain
|
|
7/13/2026 - Provided Update
Mesoblast Limited announced that it has achieved its target of at least 300 patients treated in the … Full Summary
|
BIIB Biogen |
$192.86 -7.7% |
-3.6%
 |
LEQEMBI® (lecanemab-irmb)
Treatment of Alzheimer's Disease
|
sBLA
|
7/13/2026 - FDA approved
Eisai Co., Ltd. and Biogen Inc announced that the U.S. Food and Drug Administration (FDA) has approv… Full Summary
|
ERAS Erasca |
$19.40 +8.4% |
+38.1%
 |
ERAS-0015
pan-RAS molecular glue
|
Phase 1
|
7/13/2026 - Preliminary Data
Erasca, Inc announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS m… Full Summary
|
BIIB Biogen |
$192.86 -7.7% |
-3.6%
 |
LEQEMBI® (lecanemab-irmb)
Treatment of Alzheimer's Disease
|
|
7/12/2026 - Data Presentation
Eisai Co., Ltd. and Biogen Inc. announced today that new data presented at the Alzheimer's Associat… Full Summary
|
MIRA MIRA Pharmaceuticals |
$0.92 +1.5% |
-1.8%
 |
MIRA-55
Potential treatment for anxiety and cognitive decline.
|
|
7/10/2026 - Positive Results
MIRA Pharmaceuticals, Inc. announced positive results from preclinical studies evaluating optimize… Full Summary
|
PFE Pfizer |
$24.20 -1.1% |
-7.6%
 |
PADCEV
Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
|
|
7/10/2026 - FDA approved
Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortu… Full Summary
|
MRK Merck & Co., Inc. |
$120.92 -2.5% |
+1.6%
 |
EV-303
For Certain Patients with Muscle-Invasive Bladder Cancer
|
|
7/10/2026 - FDA approved
Merck announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and K… Full Summary
|
PFE Pfizer |
$24.20 -1.1% |
-7.6%
 |
EV-303
For Certain Patients with Muscle-Invasive Bladder Cancer
|
|
7/10/2026 - FDA approved
Merck announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and K… Full Summary
|
QTTB Q32 Bio |
$21.90 +2.4% |
+73.3%
 |
Bempikibart
For Severe Alopecia Areata
|
Phase 2a Target date: July 13, 2026
|
7/10/2026 - Top-line results
Q32 Bio Inc. announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a … Full Summary
|
IONS Ionis Pharmaceuticals |
$55.70 -1.9% |
-24.0%
 |
Eplontersen
Treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
|
Phase 3
|
7/9/2026 - Provided Update
Ionis Pharmaceuticals, Inc and partner AstraZeneca announced that the CARDIO-TTRansform Phase 3 tri… Full Summary
|
GLSI Greenwich LifeSciences |
$18.73 +0.8% |
-22.2%
 |
GLSI-100
Breast cancer recurrences
|
|
7/9/2026 - Provided Update
Greenwich LifeSciences, today provided the update on the use of commercially manufactured GP2 in FLA… Full Summary
|
INMB INmune Bio |
$1.97 +5.6% |
+58.5%
 |
XPro
For treatment of Alzheimer's Disease
|
Phase 2
|
7/9/2026 - Data
INmune Bio Inc. announced new imaging data from its Phase 2 study of XPro in patients with early Alz… Full Summary
|
NEO NeoGenomics |
$14.08 -0.2% |
+26.3%
 |
PTEN IHC CDx
for Prostate Cancer
|
|
7/9/2026 - Provided Update
NeoGenomics, Inc. announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) compani… Full Summary
|
IRD Opus Genetics |
$3.79 -0.5% |
-6.1%
 |
OPGx-BEST1
For the treatment of bestrophin-1 (BEST1)-related IRD.
|
|
7/9/2026 - Provided Update
Opus Genetics, Inc. provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) ta… Full Summary
|
LLY Eli Lilly and Company |
$1,147.27 -2.9% |
+0.9%
 |
donanemab-azbt
In early symptomatic Alzheimer's disease
|
|
7/9/2026 - Abstract Presentation
Eli Lilly and Company announced it will present 16 abstracts at the 2026 Alzheimer's Association In… Full Summary
|
DCTH Delcath Systems |
$12.76 -0.8% |
+8.9%
 |
HEPZATO KIT
For the treatment of metastatic uveal melanoma (mUM).
|
Phase 2
|
7/9/2026 - Dose Update
Delcath Systems, Inc announced that the first patient has been dosed at the European Institute of O… Full Summary
|
IPSC Century Therapeutics |
$2.17 -1.6% |
-3.8%
 |
CNTY-813
for autoimmune diseases, including type 1 diabetes (T1D)
|
|
7/9/2026 - Abstract
Century Therapeutics, Inc. announced that its abstracts have been accepted for oral presentations at… Full Summary
|
INAB IN8bio |
$1.35 +1.6% |
-5.5%
 |
INB-200
For the treatment of newly diagnosed GBM solid tumors.
|
Phase 1
|
7/9/2026 - Publication
IN8bio, Inc announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-2… Full Summary
|
FBRX Forte Biosciences |
$42.82 -3.0% |
+143.8%
 |
FB102
In celiac disease
|
Phase 1b
|
7/9/2026 - Results
Forte Biosciences, Inc announced positive results from the FB102 double-blind placebo-controlled ph… Full Summary
|
FATE Fate Therapeutics |
$3.03 +0.2% |
+46.8%
 |
FT839
Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy
|
IND
|
7/9/2026 - FDA Clearance
Fate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its I… Full Summary
|
MTVA MetaVia |
$1.97 -1.3% |
+12.9%
 |
DA-1726
For The Treatment Of Obesity
|
Phase 1
|
7/9/2026 - Enrollment Update
MetaVia Inc. announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial ev… Full Summary
|
URGN Urogen Pharma |
$39.50 0.0% |
+32.9%
 |
UGN-501
Oncolytic Virus
|
IND
|
7/8/2026 - FDA Clearance
UroGen Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) cleared the Company's … Full Summary
|
ARQT Arcutis Biotherapeutics |
$26.79 -1.2% |
+9.9%
 |
ZORYVE™ (roflumilast)
Inhibitor of phosphodiesterase-4 (PDE4)
|
supplemental New Drug Application (sNDA)
|
7/8/2026 - FDA Accepted
Arcutis Biotherapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has accepte… Full Summary
|
RYTM Rhythm Pharmaceuticals |
$107.84 +0.3% |
+22.0%
 |
Setmelanotide (HO)
Hypothalamic Obesity
|
Phase 3
|
7/8/2026 - Results
Rhythm Pharmaceuticals, Inc announced that results from its pivotal Phase 3 TRANSCEND trial evaluat… Full Summary
|
CMPS Compass Pathways |
$13.14 -0.4% |
+8.7%
 |
COMP360
for treatment resistant depression (TRD).
|
|
7/7/2026 - Results
Compass Pathways plc announced today the 26-week results (Part B) from its second ongoing Phase 3 C… Full Summary
|
TVRD Tvardi Therapeutics |
$3.15 -4.9% |
+19.3%
 |
TTI-109
Pharmacodynamic Evidence of STAT3 Target Engagement
|
Phase 1
|
7/7/2026 - Results
Tvardi Therapeutics, Inc announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor… Full Summary
|
AXSM Axsome Therapeutics |
$233.35 +2.2% |
-8.6%
 |
solriamfetol
Treatment for attention deficit hyperactivity disorder (ADHD) in adults.
|
Phase 3
|
7/7/2026 - Dose Update
Axsome Therapeutics, Inc. announced that the first patient has been dosed in the FOCUS-2 Phase 3 tri… Full Summary
|
KYMR Kymera Therapeutics |
$113.22 +2.6% |
+31.3%
 |
KT-621
A potential oral treatment for asthma and other TH2 respiratory diseases.
|
|
7/7/2026 - Provided Update
Kymera Therapeutics, announced the appointment of Elizabeth Laws, Ph.D., as Senior Vice President, … Full Summary
|
AGIO Agios Pharmaceuticals |
$40.29 -0.7% |
+36.7%
 |
Mitapivat
Sickle cell disease
|
supplemental New Drug Application (sNDA)
|
7/7/2026 - FDA Accepted
Agios Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has accepted its s… Full Summary
|
ATHE Alterity Therapeutics |
$5.28 -2.0% |
+25.3%
 |
ATH434
To inhibit the aggregation of pathological proteins implicated in neurodegeneration
|
|
7/7/2026 - Meeting minutes
Alterity Therapeutics announced that it has received the official meeting minutes from its End-of Ph… Full Summary
|
TVRD Tvardi Therapeutics |
$3.15 -4.9% |
+19.3%
 |
TTI-109
Pharmacodynamic Evidence of STAT3 Target Engagement
|
Phase 1
|
7/7/2026 - Results
Tvardi Therapeutics, Inc announced Phase 1 results for TTI-109, its next-generation STAT3 inhibito… Full Summary
|
TTRX Turn Therapeutics |
$9.44 -0.3% |
+56.1%
 |
GX-03
Atopic Dermatitis Treatment
|
Phase 2
|
7/7/2026 - Provided Update
Turn Therapeutics, Inc announced the completion of a comprehensive interim analysis of its ongoing a… Full Summary
|
SABS SAB Biotherapeutics |
$3.73 +0.1% |
+12.1%
 |
SAB-142
Anti-thymocyte hpAB therapeutic
|
|
7/7/2026 - Provided Update
SAB Biotherapeutics, Inc announced that Breakthrough T1D has awarded a grant to Michael J. Haller, … Full Summary
|
ATAI Atai Beckley |
$5.44 +9.4% |
+38.7%
 |
VLS-01
For Treatment-Resistant Depression
|
Phase 2b
|
7/6/2026 - Dosing Update
AtaiBeckley Inc announced that the last patient has been dosed in Elumina, its Phase 2b clinical tr… Full Summary
|
IMRN Immuron |
$1.24 +0.8% |
+4.2%
 |
IMM-529
Oral polyclonal antibody, targeting toxin B in the human gut and neutralises main virulence factors of Clostridium infection
|
|
7/6/2026 - Provided Update
Immuron Limited announce that it has engaged Pullan Consulting to provide business development servi… Full Summary
|
NTRA Natera |
$274.73 +0.7% |
+29.5%
 |
Signatera
MRD Test for cancer therapies
|
|
7/6/2026 - Publication
Natera, Inc announced the publication of new data in JAMA Oncology, evaluating the utility of Signat… Full Summary
|
PHVS Pharvaris |
$34.54 -1.5% |
+12.4%
 |
Deucrictibant
For bradykinin-B2-receptor
|
NDA
|
7/6/2026 - FDA Accepted
Pharvaris announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Appli… Full Summary
|
PHVS Pharvaris |
$34.54 -1.5% |
+12.4%
 |
Deucrictibant
For bradykinin-B2-receptor
|
Target date: April 23, 2027
|
7/6/2026 - PDUFA Date
Pharvaris announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) target action dat… Full Summary
|
IONS Ionis Pharmaceuticals |
$55.70 -1.9% |
-24.0%
 |
ION582
Angelman syndrome
|
Phase 3
|
7/6/2026 - Enrollment Update
Ionis Pharmaceuticals, Inc. announced that it has completed enrollment in the pivotal cohort (Cohort… Full Summary
|
IONS Ionis Pharmaceuticals |
$55.70 -1.9% |
-24.0%
 |
ION582
Angelman syndrome
|
Target date: H2 2027
|
7/6/2026 - Top-line data
Ionis Pharmaceuticals, Inc announced Topline data from REVEAL anticipated in 2H 2027 - Full Summary
|
TGTX TG Therapeutics |
$55.35 +0.6% |
+11.8%
 |
BRIUMVI
For the management of autoimmune disorders
|
Phase 2
|
7/6/2026 - Clinical Trial
TG Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ubli… Full Summary
|
AGEN Agenus |
$5.76 -5.9% |
+74.4%
 |
Botensilimab
In MSS Colorectal Cancer
|
Phase 1b
|
7/6/2026 - Data
Agenus Inc announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evalu… Full Summary
|
FATE Fate Therapeutics |
$3.03 +0.2% |
+46.8%
 |
FT819
Advanced B-cell Leukemias and Lymphomas
|
|
7/6/2026 - Clinical Data
Fate Therapeutics, Inc. announced that preliminary clinical data from the Company’s off-the-shelf C… Full Summary
|
MIRA MIRA Pharmaceuticals |
$0.92 +1.5% |
-1.8%
 |
SKNY-1
For Obesity
|
|
7/6/2026 - Positive Results
MIRA Pharmaceuticals, Inc announced positive results from preclinical studies evaluating the optim… Full Summary
|
ORGO Organogenesis |
$2.27 -0.2% |
-3.2%
 |
ReNu
for Knee Osteoarthritis
|
|
7/6/2026 - Provided Update
Organogenesis Holdings Inc. announced that the U.S. Food and Drug Administration (FDA) has complete… Full Summary
|
ORGO Organogenesis |
$2.27 -0.2% |
-3.2%
 |
ReNu
for Knee Osteoarthritis
|
Target date: April 27, 2027
|
7/6/2026 - PDUFA Date
Organogenesis Holdings Inc. announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) … Full Summary
|
GMAB Genmab A/S |
$28.55 -0.9% |
+13.8%
 |
TEPKINLY
For the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
|
|
7/6/2026 - Marketing authorization
AbbVie announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (ep… Full Summary
|
ABBV AbbVie |
$244.01 -1.6% |
+7.2%
 |
TEPKINLY
For the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
|
|
7/6/2026 - Marketing authorization
AbbVie announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (ep… Full Summary
|
HCM HUTCHMED |
$11.23 +0.8% |
+2.5%
 |
savolitinib
Tyrosine kinase inhibitor
|
|
7/2/2026 - Conditional approval
HUTCHMED (China) Limited announces that the New Drug Application (NDA) for ORPATHYS® (savolitinib)… Full Summary
|
RVMD Revolution Medicines |
$186.44 +1.4% |
+21.2%
 |
Zoldonrasib
for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC
|
Phase 1/2
|
7/2/2026 - Results
Revolution Medicines announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, it… Full Summary
|
BIIB Biogen |
$192.86 -7.7% |
-3.6%
 |
BYOOVIZ
Retinal vascular disorders
|
|
7/1/2026 - Provided Update
Harrow announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar re… Full Summary
|
NCEL NLS Pharmaceutics |
$3.92 -2.0% |
+21.4%
 |
NCEL-101
for Type 1 Diabetes
|
FDA Type B Meeting
|
7/1/2026 - FDA Meeting
NewcelX Ltd. announced the successful completion of its Type B Pre-IND meeting with the U.S. Food an… Full Summary
|
VRTX Vertex Pharmaceuticals |
$478.30 -0.4% |
+7.5%
 |
CASGEVY
For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
|
|
7/1/2026 - FDA approved
Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA… Full Summary
|
NBIX Neurocrine Biosciences |
$171.92 -1.3% |
+7.6%
 |
crinecerfont
For the Treatment of Congenital Adrenal Hyperplasia (CAH)
|
Phase 2
|
7/1/2026 - Clinical Study
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the s… Full Summary
|
ACIU AC Immune |
$2.47 +0.6% |
+6.7%
 |
ACI-24 (AD)
Alzheimer’s Disease (AD)
|
|
6/30/2026 - Interim Data
AC Immune SA announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients wit… Full Summary
|
BEAT HeartBeam |
$0.54 -6.0% |
-28.3%
 |
ALIGN-ACS
for heart attack detection
|
|
6/30/2026 - Enrollment Update
HeartBeam, Inc. announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating… Full Summary
|
NVCR NovoCure |
$15.59 -3.1% |
-12.3%
 |
gem/nab-pac
Metastatic Pancreatic Cancer
|
|
6/30/2026 - CE Mark
Novocure announced that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment … Full Summary
|
ADCT ADC Therapeutics |
$1.25 -0.4% |
+18.1%
 |
ZYNLONTA
In patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
|
Phase 1b
|
6/30/2026 - Enrollment Update
ADC Therapeutics SA announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinic… Full Summary
|
ADCT ADC Therapeutics |
$1.25 -0.4% |
+18.1%
 |
ZYNLONTA
In patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
|
Target date: Q4 2026
|
6/30/2026 - Data
ADC Therapeutics SA announced that the Full data expected in fourth quarter of 2026 Full Summary
|
SCYX SCYNEXIS |
$4.68 +4.4% |
+10.6%
 |
SCY-770
Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 1
|
6/30/2026 - Study Initiation
SCYNEXIS, Inc. announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and dire… Full Summary
|
COGT Cogent Biosciences |
$37.77 +0.8% |
+14.1%
 |
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
NDA
|
6/30/2026 - NDA submission
Cogent Biosciences, Inc. announced it has submitted its New Drug Application (NDA) to the U.S. Food … Full Summary
|
DSGN Design Therapeutics |
$13.96 +0.8% |
+27.3%
 |
DT-818
GeneTAC® candidates
|
Phase 1
|
6/30/2026 - Dose Update
Design Therapeutics, Inc. announced the initiation of patient dosing in its Phase 1 multiple-ascend… Full Summary
|
VTGN VistaGen Therapeutics |
$0.25 -2.7% |
-57.3%
 |
Fasedienol
For the acute treatment of social anxiety disorder (SAD).
|
Phase 3
|
6/30/2026 - Top-line results
Vistagen announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for … Full Summary
|
STOK Stoke Therapeutics |
$29.23 -0.8% |
-2.0%
 |
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
|
6/30/2026 - Enrollment Update
Stoke Therapeutics, Inc announced the completion of enrollment of 162 patients into the Phase 3 EMP… Full Summary
|
STOK Stoke Therapeutics |
$29.23 -0.8% |
-2.0%
 |
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
Target date: Q1 2027
|
6/30/2026 - rolling submission
Stoke Therapeutics, Inc to initiate a rolling New Drug Application (NDA) submission to the U.S. Food… Full Summary
|
STOK Stoke Therapeutics |
$29.23 -0.8% |
-2.0%
 |
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
Phase 3 Target date: Q3 2026
|
6/30/2026 - Data readout
Stoke Therapeutics, Inc announced that Phase 3 data readout is anticipated in the third quarter of … Full Summary
|
CADL Candel Therapeutics |
$9.68 +0.4% |
+13.1%
 |
CAN-2409
Prostate cancer
|
Phase 3
|
6/30/2026 - Pivotal Study
Candel Therapeutics, Inc. announced the initiation of the global pivotal phase 3 AURORA trial (NCT07… Full Summary
|
MBRX Moleculin Biotech |
$2.29 +3.4% |
-13.4%
 |
Annamycin
Soft tissue sarcoma (STS) lung metastases
|
|
6/30/2026 - Results
Moleculin Biotech, Inc., announced positive preliminary unblinded efficacy results from the first 45… Full Summary
|
SRPT Sarepta Therapeutics |
$18.32 -2.7% |
+19.6%
 |
AMONDYS 45
treatment of Duchenne muscular dystrophy (DMD).
|
supplemental New Drug Application (sNDA)
|
6/30/2026 - FDA Accepted
Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted … Full Summary
|
LRMR Larimar Therapeutics |
$3.72
|
+7.2%
 |
nomlabofusp
For Friedreich's Ataxia
|
|
6/29/2026 - Provided Update
Larimar Therapeutics, announced it has submitted the first module of its rolling Biologics License … Full Summary
|
BIIB Biogen |
$192.86 -7.7% |
-3.6%
 |
diranersen
Alzheimer’s disease
|
|
6/29/2026 - Data Presentation
Biogen Inc. announced it will present new data across its Alzheimer’s disease portfolio at the Alzhe… Full Summary
|
VTRS Viatris |
$16.26 -0.8% |
-1.4%
 |
VR-205
Immunoglobulin A Nephropathy
|
Phase 3
|
6/29/2026 - Top-line results
Viatris Inc announced positive top-line results from a Phase 3 clinical trial evaluating the efficac… Full Summary
|
MSLE Satellos Bioscience |
$9.06 -7.5% |
+57.6%
 |
SAT-3247
Duchenne muscular dystrophy (DMD)
|
Fast Track
|
6/29/2026 - Designation Grant
Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fas… Full Summary
|
MRK Merck & Co., Inc. |
$120.92 -2.5% |
+1.6%
 |
Doravirine/Islatravir
In adults with HIV-1 infection
|
|
6/29/2026 - Provided Update
Merck announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assista… Full Summary
|